Mizuho Securities USA LLC Purchases 3,605 Shares of Humana Inc. (NYSE:HUM)

Mizuho Securities USA LLC raised its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 46.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,412 shares of the insurance provider's stock after purchasing an additional 3,605 shares during the period. Mizuho Securities USA LLC's holdings in Humana were worth $2,895,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Transcend Capital Advisors LLC raised its stake in shares of Humana by 399.7% in the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider's stock valued at $924,000 after acquiring an additional 2,914 shares during the period. FNY Investment Advisers LLC lifted its holdings in Humana by 6,647.5% in the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider's stock worth $6,916,000 after acquiring an additional 26,856 shares during the last quarter. Retirement Systems of Alabama increased its position in Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock worth $55,563,000 after buying an additional 192,801 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Humana by 7.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider's stock valued at $244,811,000 after purchasing an additional 65,735 shares during the last quarter. Finally, PDT Partners LLC grew its holdings in Humana by 190.0% in the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider's stock worth $1,286,000 after buying an additional 2,660 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Remove Ads

Humana Price Performance

HUM traded down $6.43 during midday trading on Friday, reaching $263.95. 967,907 shares of the company's stock were exchanged, compared to its average volume of 1,758,856. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business has a 50-day simple moving average of $270.51 and a two-hundred day simple moving average of $274.93. The firm has a market capitalization of $31.86 billion, a price-to-earnings ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. Humana Inc. has a one year low of $213.31 and a one year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Friday, March 28th. Humana's payout ratio is currently 35.58%.

Analyst Upgrades and Downgrades

A number of analysts have commented on HUM shares. Cantor Fitzgerald restated a "neutral" rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Truist Financial increased their price target on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Barclays increased their target price on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. StockNews.com downgraded shares of Humana from a "buy" rating to a "hold" rating in a research report on Tuesday, March 18th. Finally, Morgan Stanley dropped their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Eighteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Humana has an average rating of "Hold" and a consensus target price of $285.68.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.37% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.